Aeviant’s public scientific work concerns norepinephrine regulation, the α2A-adrenergic autoreceptor, and the pharmacology needed to distinguish positive allosteric modulation from direct agonism.
The reviews separate established biology, preclinical evidence, Aeviant interpretation, and program objectives. Each states the limitations of the cited work and the boundary between published findings and the AVX-1 thesis.
AVX-1 remains a computational research program. No physical molecule has been synthesized, no assay has been run, and none of its intended pharmacological properties has been demonstrated experimentally.
Science content reviewed July 16, 2026.
Norepinephrine signalling is regulated across central and peripheral tissues through synthesis, release, reuptake, metabolism, receptor signalling, and feedback. This review describes the public biology relevant to AVX-1 and the limits of what can be inferred from it.
The α2A-adrenergic autoreceptor participates in inhibitory norepinephrine feedback. Its effects vary by tissue, circuit, activity pattern, and experimental context. This review separates that published biology from Aeviant’s interpretation and the AVX-1 program objective.
Ongoing tonic activity and transient phasic responses vary with vigilance, sensory events, task state, and experimental context. This review describes the underlying observations and why they do not establish a pharmacological outcome for AVX-1.
Public claims organized by evidence type, relevance, limitations, and source, with Aeviant interpretation kept separate from published findings.
Program-specific context is available in the AVX-1 review.